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Fig.　1　Clinical photographs of (a) chest and abdomen, (b) back, and (c) left shoulder at the fi rst 
visit, and (d) abdomen at 48 hours after intake of Coughcode®-N combination tablets.
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Dear Editor
Maculopapular-Type Drug Eruption
Caused by CoughcodeⓇ-N
Combination Tablets
CoughcodeⓇ-N combination tablets (Mylan Pharma-
ceutical, Tokyo, Japan) are oral antitussive tablets
consisting of acetaminophen, bromovalerylurea, dihy-
drocodeine phosphate, diphenhydramine salicylate,
diprophylline, and dl-methylephedrine hydrochloride.
Here, we describe a case of maculopapular-type drug
eruption caused by CoughcodeⓇ -N that was repro-
duced by oral challenge test.
An 18-year-old Japanese woman visited our depart-
ment for diagnosis of a faint erythematous rash over
the whole body. She stated that she had taken
CoughcodeⓇ-N and ToclaseⓇ (pentoxyverine citrate;
Dainippon Sumitomo Pharma, Osaka, Japan) for 4
days and over-the-counter medication Kaigen Ⓡ
(Kaigen, Osaka, Japan) for 6 days for a cough and
common cold, respectively. Three days before her
first visit to our department, she noticed the eruption.
Therefore, she had stopped all drugs 2 days before
her first visit based on her own judgement.
In an initial physical examination in our depart-
ment, she had recovered from the common cold.
Faint erythematous and maculopapular lesions were
present over the whole body (Fig. 1a-c), but there
were no mucosal lesions associated with Stevens-
Johnson syndrome. Laboratory tests were within nor-
mal limits, including complete blood cell count, liver
and kidney functions, and serum levels of C-reactive
protein (CRP). However, the eosinophil percentage
(10.9%; normal 0-8%) was elevated. On the basis of
her history and blood test results, drug eruption
caused by CoughcodeⓇ-N, ToclaseⓇ or KaigenⓇ was
suspected.
Lymphocyte transformation tests (LTTs) to Cough-
codeⓇ-N (stimulation index 0.9; normal <1.8) and To-
claseⓇ ( stimulation index 0.8 ; normal <1.8 ) were
negative. The eruption disappeared in 12 days with
oral administration of fexofenadine hydrochloride 120
mgday and topical application of clobetasone bu-
tyrate 0.05% on her neck and difluprednate 0.05% on
her trunk and extremities. Patch tests were per-
formed using CoughcodeⓇ-N (50%, 30%, 10% in petro-
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latum), ToclaseⓇ (20% in petrolatum), and KaigenⓇ
(50%, 30%, 10% in petrolatum) according to the guide-
lines of the International Contact Dermatitis Re-
search Group. Petrolatum was used as a vehicle. All
patch tests were negative. Therefore, oral challenge
tests were performed in an inpatient setting using
CoughcodeⓇ-N (110, 15, 12, 1 therapeutic dose),
ToclaseⓇ (110, 15, 12, 1 therapeutic dose), and
KaigenⓇ (110, 15, 12, 1 therapeutic dose). The
test reactions to ToclaseⓇ and KaigenⓇ were all
negative. However, the skin eruption was reproduced
over the whole body within 2 hours after taking a
CoughcodeⓇ -N combination tablet at 1 therapeutic
dose. The eruption reached its peak intensity after 48
hours (Fig. 1d). At this time, laboratory tests were
within normal limits, including eosinophil percent-
age, but mild fever (37.1°) and general malaise were
present.
Based on these results, we diagnosed this case as a
maculopapular-type drug eruption caused by Cough-
codeⓇ-N combination tablets. The eruptions, as well
as mild fever and general malaise, disappeared with-
out treatment within 4 days. Patch tests were per-
formed individually for three of the components of
CoughcodeⓇ -N (20% acetaminophen, 20% bromova-
lerylurea, 20% diprophylline) in an outpatient setting,
and all were negative. Patch tests to the other three
components (dihydrocodeine phosphate, diphenhy-
dramine salicylate, dl-methylephedrine hydrochlo-
ride) were not performed because we were unable to
obtain these drugs individually. Among the 6 compo-
nents, acetaminophen is often used for relief of fever
and aches and pains associated with many conditions.
Thus, the patient requested an oral challenge test to
acetaminophen to check for the allergy. Tests using
acetaminophen (110, 15, 12, 1 therapeutic dose)
were performed in an inpatient setting, and all were
negative.
The CoughcodeⓇ-N combination tablet was devel-
oped in 2002 and is only available in Japan. It is ap-
proved for cough suppression, relief of pain, and anti-
pyresis in common cold syndrome and for cough sup-
pression in bronchitis. CoughcodeⓇ-N is a modified
tablet in which phenacetin and barbiturates in the
CoughcodeⓇ tablet were replaced by acetaminophen.
CoughcodeⓇ tablets were often used for cough and
common cold and for bronchitis until 2001, but the
distribution was stopped because of the occurrence
of chronic renal failure due to long-term use of drugs
including phenacetin. There have been cases of fixed
drug eruptions caused by CoughcodeⓇ tablets,1-7 but
to our knowledge this report and that of Sato et al.8
are the only two descriptions of drug allergy induced
by Coughcode Ⓡ -N combination tablets in the
English- and Japanese-language literature. Sato et al.8
reported a case of Stevens-Johnson syndrome caused
by acetaminophen in CoughcodeⓇ-N given for treat-
ment of cough and common cold for 4 days before
the appearance of the eruption. LTTs to Cough-
codeⓇ-N and acetaminophen were positive in Sato et
al.,8 while the patient in our case had a negative LTT
and patch test reaction to CoughcodeⓇ-N, but a posi-
tive oral challenge test. However, acetaminophen was
not the causative drug based on a negative oral chal-
lenge test. Thus, we were able to identify the causa-
tive drug of the eruption, but not the causative com-
ponent. This component may have been one of the 3
untested components. Alternatively, the drug erup-
tion might have been due to a cooperative mecha-
nism involving plural components in CoughcodeⓇ-N,
similar to the multiple fixed drug eruptions due to
drug combination.9,10 Cross-sensitivity reactions may
occur with chemically related drugs. However, all the
components of CoughcodeⓇ -N were not chemically
similar or related. Therefore, in our case the underly-
ing mechanism of drug eruption due to a drug combi-
nation was unclear, but the possibility of some un-
known chemical interaction occurring in the manu-
facture of the combined preparation might also be
considered as described by Verbov.10
Oral administration of CoughcodeⓇ-N combination
tablets is a useful and convenient treatment for cough
and common cold because of the combined effects on
symptoms. However, medical practitioners should be
aware of potentially allergic reactions to Cough-
codeⓇ -N, with recognition that identification of the
causative component might be difficult compared to a
product containing a single agent.
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